What is Zacks Research’s Estimate for Exelixis Q3 Earnings?

Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at Zacks Research upped their Q3 2026 EPS estimates for shares of Exelixis in a report issued on Friday, March 6th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $0.74 per share for the quarter, up from their previous estimate of $0.71. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ FY2026 earnings at $2.96 EPS, Q1 2027 earnings at $0.82 EPS and FY2028 earnings at $4.23 EPS.

Several other equities research analysts have also recently issued reports on the company. Wells Fargo & Company lifted their price objective on Exelixis from $30.00 to $35.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Barclays increased their target price on Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. UBS Group set a $41.00 price target on Exelixis in a research note on Monday, January 5th. Stifel Nicolaus boosted their price target on Exelixis from $43.00 to $44.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Finally, Citigroup downgraded Exelixis from a “market outperform” rating to an “underperform” rating in a research note on Monday, January 5th. Ten equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $46.94.

Exelixis Stock Up 0.6%

EXEL opened at $41.54 on Monday. The company has a market cap of $10.79 billion, a PE ratio of 15.00, a price-to-earnings-growth ratio of 0.93 and a beta of 0.41. Exelixis has a twelve month low of $32.38 and a twelve month high of $49.62. The company has a 50-day moving average price of $43.57 and a 200 day moving average price of $41.60.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. The business had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $0.55 earnings per share.

Insiders Place Their Bets

In other news, EVP Patrick J. Haley sold 67,814 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total value of $2,951,265.28. Following the completion of the sale, the executive vice president directly owned 381,908 shares in the company, valued at $16,620,636.16. This represents a 15.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bob Oliver sold 30,250 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $43.81, for a total value of $1,325,252.50. Following the completion of the sale, the director directly owned 21,120 shares of the company’s stock, valued at approximately $925,267.20. This represents a 58.89% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 362,849 shares of company stock worth $15,917,463. 2.82% of the stock is currently owned by insiders.

Institutional Trading of Exelixis

Several large investors have recently added to or reduced their stakes in EXEL. Richardson Financial Services Inc. raised its holdings in shares of Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 292 shares during the period. Anchor Investment Management LLC grew its holdings in shares of Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares during the period. Motiv8 Investments LLC purchased a new stake in shares of Exelixis in the 4th quarter valued at approximately $26,000. Root Financial Partners LLC acquired a new stake in shares of Exelixis during the 3rd quarter worth approximately $28,000. Finally, Acumen Wealth Advisors LLC acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $29,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.